Platelet-dependent hemostatic processes

Platelet-dependent hemostatic processes refer to the complex physiological sequence of platelet adhesion, activation, and aggregation required to stop bleeding following vascular injury [1]. This process begins when platelets adhere to exposed subendothelial collagen and von Willebrand factor, triggering intracellular signaling that leads to the release of granules and the recruitment of additional platelets [1, 3]. Key molecular mediators in this pathway include adenosine diphosphate (ADP), thromboxane A2, and thrombin, which amplify the activation signal [1]. The final common pathway of platelet aggregation is the activation of the glycoprotein IIb/IIIa receptor, which binds fibrinogen to form a stable plug [1, 2]. While essential for maintaining vascular integrity, pathological activation of these processes can lead to arterial thrombosis, which is the underlying cause of most myocardial infarctions and strokes [2, 3]. Pharmacological modulation of these processes is a cornerstone of cardiovascular medicine, utilizing drugs that target specific molecular components such as the P2Y12 receptor or cyclooxygenase-1 to prevent clot formation [2]. Common antiplatelet agents include aspirin, P2Y12 inhibitors like clopidogrel, and glycoprotein IIb/IIIa inhibitors [3, 5]. However, the primary therapeutic challenge remains balancing the prevention of thrombosis with the inherent risk of bleeding complications [5].

Other names

Primary hemostasisPlatelet activationPlatelet aggregationThrombus formation

Inhibition of platelet aggregation through various mechanisms including irreversible inhibition of cyclooxygenase-1 (COX-1), antagonism of the P2Y12 adenosine diphosphate (ADP) receptor, blockade of the glycoprotein IIb/IIIa receptor, and antagonism of protease-activated receptor-1 (PAR-1) [2, 3].